Total Payments
$430,778
2024 Payments
$14,678
Companies
72
Transactions
1,606
Medicare Patients
6,536
Medicare Billing
$809,077
Payment Breakdown by Category
Other$274,279 (63.7%)
Consulting$83,453 (19.4%)
Food & Beverage$34,724 (8.1%)
Research$21,319 (4.9%)
Travel$16,672 (3.9%)
Education$330.30 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $247,229 | 107 | 57.4% |
| Consulting Fee | $83,453 | 29 | 19.4% |
| Food and Beverage | $34,724 | 1,371 | 8.1% |
| Honoraria | $27,050 | 14 | 6.3% |
| Unspecified | $21,319 | 27 | 4.9% |
| Travel and Lodging | $16,672 | 53 | 3.9% |
| Education | $330.30 | 5 | 0.1% |
Payments by Type
General
$409,458
1,579 transactions
Research
$21,319
21 transactions
Ownership
$0
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $125,743 | 176 | $0 (2024) |
| Allergan, Inc. | $84,607 | 154 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $39,873 | 200 | $0 (2024) |
| Lundbeck LLC | $29,007 | 62 | $0 (2024) |
| IMPEL PHARMACEUTICALS INC. | $21,983 | 53 | $0 (2023) |
| Biohaven Pharmaceuticals, Inc. | $21,384 | 85 | $0 (2021) |
| ABBVIE INC. | $21,021 | 140 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $17,322 | 55 | $0 (2021) |
| Supernus Pharmaceuticals, Inc. | $14,387 | 67 | $0 (2022) |
| Promius Pharma LLC | $12,777 | 33 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,678 | 213 | Eli Lilly and Company ($8,530) |
| 2023 | $20,854 | 174 | PFIZER INC. ($9,840) |
| 2022 | $39,346 | 213 | IMPEL PHARMACEUTICALS INC. ($18,594) |
| 2021 | $92,720 | 263 | Amgen Inc. ($27,238) |
| 2020 | $96,067 | 190 | Allergan, Inc. ($47,487) |
| 2019 | $49,475 | 174 | Amgen Inc. ($28,068) |
| 2018 | $88,744 | 220 | Amgen Inc. ($42,043) |
| 2017 | $28,893 | 159 | Avanir Pharmaceuticals, Inc. ($8,090) |
All Payment Transactions
1,606 individual payment records from CMS Open Payments — Page 1 of 65
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Currax Pharmaceuticals LLC | ONZETRA XSAIL (Drug), CONTRAVE | Food and Beverage | In-kind items and services | $10.68 | General |
| Category: Neurology | ||||||
| 12/20/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $16.70 | General |
| Category: Endocrinology | ||||||
| 12/18/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $6.24 | General |
| Category: NEUROLOGY | ||||||
| 12/16/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $11.67 | General |
| Category: NEUROLOGY | ||||||
| 12/11/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: PAIN | ||||||
| 12/10/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $21.86 | General |
| Category: NEUROLOGY | ||||||
| 12/09/2024 | Currax Pharmaceuticals LLC | ONZETRA XSAIL (Drug), CONTRAVE | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: Neurology | ||||||
| 12/09/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $6.02 | General |
| Category: NEUROLOGY | ||||||
| 12/04/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: NEUROLOGY | ||||||
| 12/03/2024 | Currax Pharmaceuticals LLC | ONZETRA XSAIL (Drug), CONTRAVE | Food and Beverage | In-kind items and services | $7.11 | General |
| Category: Neurology | ||||||
| 12/02/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $27.33 | General |
| Category: NEUROSCIENCE | ||||||
| 11/26/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $30.36 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/26/2024 | Currax Pharmaceuticals LLC | ONZETRA XSAIL (Drug), CONTRAVE | Food and Beverage | In-kind items and services | $9.29 | General |
| Category: Neurology | ||||||
| 11/25/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: Neurology | ||||||
| 11/25/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $4.57 | General |
| Category: NEUROLOGY | ||||||
| 11/22/2024 | Currax Pharmaceuticals LLC | ONZETRA XSAIL (Drug) | Food and Beverage | In-kind items and services | $12.23 | General |
| Category: Neurology | ||||||
| 11/21/2024 | SCILEX PHARMACEUTICALS INC. | ELYXYB - CELECOXIB (Drug) | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: Pain Management | ||||||
| 11/21/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $9.60 | General |
| Category: NEUROLOGY | ||||||
| 11/20/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: PAIN | ||||||
| 11/20/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $8.63 | General |
| Category: NEUROLOGY | ||||||
| 11/19/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Neurology | ||||||
| 11/16/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $147.59 | General |
| Category: NEUROLOGY | ||||||
| 11/16/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $57.30 | General |
| Category: NEUROSCIENCE | ||||||
| 11/15/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $25.96 | General |
| Category: Neuroscience | ||||||
| 11/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $130.85 | General |
| Category: FACIAL AESTHETICS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | PFIZER INC. | $9,308 | 5 |
| PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | Eli Lilly and Company | $8,514 | 2 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $1,436 | 4 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $571.00 | 2 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $571.00 | 2 |
| PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | Eli Lilly and Company | $347.00 | 1 |
| A PHASE 3B MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY STUDY OF LY2951742 -GALCANEZUMAB- IN PATIENTS WITH EPISODIC OR CHRONIC CLUSTER HEADACHE | Eli Lilly and Company | $263.00 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | Eli Lilly and Company | $241.05 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $52.80 | 1 |
| A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | Eli Lilly and Company | $11.09 | 1 |
| A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | Eli Lilly and Company | $4.26 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,493 | 5,900 | $756,934 | $186,707 |
| 2022 | 18 | 1,516 | 5,704 | $762,161 | $195,406 |
| 2021 | 25 | 1,978 | 6,711 | $869,766 | $235,454 |
| 2020 | 19 | 1,549 | 5,001 | $747,420 | $191,510 |
Total Patients
6,536
Total Services
23,316
Medicare Billing
$809,077
Procedure Codes
82
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 70551 | Mri scan of brain without contrast | Office | 2023 | 313 | 323 | $195,524 | $46,194 | 23.6% |
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 172 | 193 | $248,005 | $45,820 | 18.5% |
| 70546 | Mri scan of blood vessels of head before and after contrast | Office | 2023 | 64 | 64 | $68,480 | $16,205 | 23.7% |
| 70544 | Mri scan of blood vessels of head without contrast | Office | 2023 | 93 | 94 | $57,810 | $14,752 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 109 | 152 | $22,800 | $14,064 | 61.7% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 100 | 100 | $28,500 | $12,789 | 44.9% |
| 70549 | Mri scan of blood vessels of neck before and after contrast | Office | 2023 | 30 | 31 | $33,170 | $8,210 | 24.8% |
| 70450 | Ct scan head or brain without contrast | Office | 2023 | 85 | 94 | $25,474 | $7,443 | 29.2% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Office | 2023 | 107 | 107 | $19,795 | $6,096 | 30.8% |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | Office | 2023 | 242 | 2,342 | $16,394 | $3,307 | 20.2% |
| 70496 | Ct scan of blood vessels of head with contrast | Office | 2023 | 17 | 17 | $11,475 | $3,022 | 26.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $4,275 | $2,308 | 54.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 16 | $3,200 | $1,973 | 61.7% |
| 72141 | Mri scan of upper spinal canal without contrast | Office | 2023 | 13 | 13 | $7,995 | $1,222 | 15.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 12 | 12 | $2,640 | $1,195 | 45.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 15 | $1,500 | $973.98 | 64.9% |
| 76376 | 3d radiographic procedure | Office | 2023 | 38 | 47 | $7,473 | $853.66 | 11.4% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 26 | 2,150 | $2,150 | $246.44 | 11.5% |
| A9585 | Injection, gadobutrol, 0.1 ml | Office | 2023 | 12 | 98 | $196.00 | $25.53 | 13.0% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 13 | 13 | $78.00 | $6.64 | 8.5% |
| 70551 | Mri scan of brain without contrast | Office | 2022 | 314 | 320 | $194,240 | $48,340 | 24.9% |
| 70553 | Mri scan of brain before and after contrast | Office | 2022 | 166 | 176 | $225,875 | $42,853 | 19.0% |
| 70546 | Mri scan of blood vessels of head before and after contrast | Office | 2022 | 67 | 71 | $75,970 | $17,721 | 23.3% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 122 | 124 | $35,340 | $17,488 | 49.5% |
| 70544 | Mri scan of blood vessels of head without contrast | Office | 2022 | 90 | 91 | $55,965 | $15,080 | 26.9% |
About Dr. Laszlo Mechtler, MD
Dr. Laszlo Mechtler, MD is a Neurology healthcare provider based in Amherst, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1710978598.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Laszlo Mechtler, MD has received a total of $430,778 in payments from pharmaceutical and medical device companies, with $14,678 received in 2024. These payments were reported across 1,606 transactions from 72 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($247,229).
As a Medicare-enrolled provider, Mechtler has provided services to 6,536 Medicare beneficiaries, totaling 23,316 services with total Medicare billing of $809,077. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Amherst, NY
- Active Since 11/02/2005
- Last Updated 05/29/2018
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1710978598
Products in Payments
- Aimovig (Biological) $110,909
- UBRELVY (Drug) $42,779
- BOTOX (Biological) $35,926
- NURTEC ODT (Drug) $35,243
- VYEPTI (Biological) $28,847
- AJOVY (Biological) $23,984
- Trudhesa (Drug) $21,983
- ONZETRA Xsail (Drug) $16,165
- TROKENDI XR (Drug) $14,280
- AJOVY (Drug) $11,110
- Zembrace (Drug) $9,256
- BOTOX (Drug) $8,739
- ZEMBRACE SYMTOUCH (Drug) $6,322
- BOTOX - MIGRAINE (Drug) $5,460
- ONZETRA XSAIL (Drug) $5,317
- QULIPTA (Drug) $3,936
- TREXIMET (Drug) $2,866
- BOTOX CHRONIC MIGRAINE (Drug) $2,129
- MRI Und Other Opt (Device) $1,168
- NUEDEXTA (Drug) $1,165
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Amherst
Nicolas Saikali, Md, MD
Neurology — Payments: $1.7M
Neurology $1.7M
Dr. Jennifer Mcvige, M.d, M.D
Neurology — Payments: $1.0M
Neurology $1.0M
Bennett Myers, M.d, M.D
Neurology — Payments: $538,477
Neurology $538,477
Dr. Wisam Elmalik, M.d, M.D
Neurology — Payments: $321,171
Neurology $321,171
Dr. Bela Ajtai, Md, Phd, MD, PHD
Neurology — Payments: $135,293
Neurology $135,293
Tomas Holmlund, M.d, M.D
Neurology — Payments: $75,151
Neurology $75,151